FH

Stoneridge Launching MirrorEye® Camera Monitor System with Volvo Trucks on Global Heavy-Duty Truck Platforms

Retrieved on: 
Tuesday, February 27, 2024
OE, SRI, Safety, CO2, VNL, FH, Volvo

NOVI, Mich., Feb. 27, 2024 /PRNewswire/ -- Stoneridge Inc. (NYSE: SRI) today announced its MirrorEye® Camera Monitor System will launch on Volvo's all-new heavy-duty truck platforms. The system will be featured on the Volvo FH Aero in Europe, Australia, Asia, and Africa and the All-New VNL in North America.

Key Points: 
  • Industry-leading vision system technology to be featured on FH Aero, All-New VNL models
    NOVI, Mich., Feb. 27, 2024 /PRNewswire/ -- Stoneridge Inc. (NYSE: SRI) today announced its MirrorEye® Camera Monitor System will launch on Volvo's all-new heavy-duty truck platforms.
  • The system will be featured on the Volvo FH Aero in Europe, Australia, Asia, and Africa and the All-New VNL in North America.
  • "We're proud to support and advance Volvo's drive to net-zero emissions," said Jim Zizelman, president and CEO of Stoneridge.
  • For more information and technical specs about the Volvo All-New VNL platform, click here .

Managing the transition to central bank digital currency

Retrieved on: 
Wednesday, February 14, 2024
Technical report, Regulation, Private sector, Aircraft, Interest, RTD, Policy, CES, Research Papers in Economics, A.2, The Economic Journal, RTK, International Settlement, F30, Next, A.6, Community business development corporation, A.7, UIP, American Economic Journal, National bank, Paper, Bank, Macroeconomics, Economy, Central bank, GSS, Capital, XF, Elasticity, Government, Competition, Credit, Social science, Volatility, Domestic, European, IH, Investment, A.13, SSRN, Intermediate, A.5, Section 2, AP, Probability, Review of Economic Dynamics, Foreign, Journal of Monetary Economics, Remuneration, Uncertainty, Medical classification, Bank of England, Shock, DF, Bank of Canada, ISSN, CIA, European Central Bank, Survival, RD, FH, KT, N B, Cuore, Monetary economics, Section 3, Welfare, Iteration, DSGE, Blessthefall, Reserve, Website, GBP, Calibration, RDC, Parameter, DCT, GDP, KF, Sokol, Rebelo, Figure, De Nederlandsche Bank, Parity, TFP, Depreciation, Total, BIS, Home, Section 4, Attitude, Acquisition, JEL, Cross, Household, FF, QT, Control, Swiss, Motion, ECB, M. A, GF, A.9, RT, Cattolica, Exercise, C.2, XH, Tax, Crowding, European Parliament, Literature, Reproduction, Political economy, Committee, Exp, E50, Uhlig, EUR, IID, Digital currency, Tourism, American Economic Review, Manuscript, AG, A.8, Research, F41, Friction, Public sector, PDF, U N, YH, Cryptocurrency
Key Points: 

    Tecumseh Introduces New A2L, R290, and DC-Powered Refrigeration Technologies at AHR Expo 2024

    Retrieved on: 
    Tuesday, January 16, 2024
    VDC, ANN, RG, Refrigeration, Argus, BESS, AHR, Air conditioning, Electronics, HG, VS, AG, ASHRAE, McCormick Place, College of Engineering (KNUST), AJ2, EV, Atmosphere, Hydrofluorocarbon, ARGUS, UL, Tecumseh Products, FH

    ANN ARBOR, Mich., Jan. 16, 2024 /PRNewswire-PRWeb/ -- Tecumseh Products Company LLC, a global leader and innovator of commercial refrigeration technologies, will showcase its latest compressor and systems offering at McCormick Place (booth #S6720) during the upcoming AHR Expo 2024 in Chicago. Tecumseh's new products are optimized for low-GWP refrigerants in commercial refrigeration, heat pump climate control, and EV & transport refrigeration applications. Some highlights include A2L-ready rotary compressors for heat pumps, 12HP Argus condensing unit with paired CRIOS unit coolers, VDC eCompressors for electronics and mobile transport cooling and refrigeration. The year 2024 marks Tecumseh's 90th year anniversary since it was originally founded in 1934. Tecumseh will kick-off a series of its global anniversary celebrations during AHR Expo.

    Key Points: 
    • Tecumseh's new products are optimized for low-GWP refrigerants in commercial refrigeration, heat pump climate control, and EV & transport refrigeration applications.
    • Tecumseh will kick-off a series of its global anniversary celebrations during AHR Expo.
    • At AHR Expo, Tecumseh will display rotary compressors which are optimized for hot water heat pump applications with A2L refrigerants.
    • Tecumseh will launch a series of celebrations in 2024 commencing at the AHR Expo, as they commemorate their historic 90th-year anniversary.

    Omron Announces Muller Technology as a Certified Systems Integrator Partner

    Retrieved on: 
    Friday, January 12, 2024
    Automation, Creativity, Omron, Marketing, AMR, FH, Industrial design

    HOFFMAN ESTATE, Ill., Jan. 12, 2024 /PRNewswire-PRWeb/ -- Omron Automation Americas recently announced Muller Technology as a new partner in its Certified Systems Integrator program. Based in Fort Collins, Colorado, with a Head office in Conthey, Switzerland, Muller cultivates a strong passion and creativity to develop pioneering solutions for customers.

    Key Points: 
    • Industry-leading automation solutions provider Omron Automation Americas welcomes a new certified systems integrator partner Muller Technology CO, Inc., a full-service provider of automation solutions.
    • HOFFMAN ESTATE, Ill., Jan. 12, 2024 /PRNewswire-PRWeb/ -- Omron Automation Americas recently announced Muller Technology as a new partner in its Certified Systems Integrator program.
    • "Working together with Omron, we are able to leverage their advanced automation solutions to develop pioneering and innovative solutions for our valued customers," says Marty Chiaramonte, VP of Sales and Marketing from Muller Technology.
    • Muller Technology has been collaborating with Omron in developing machines and automation systems for end users for many years.

    Grand Ming Group Holdings Limited Announces Interim Results for the Six Months Ended 30 September 2023

    Retrieved on: 
    Thursday, November 9, 2023
    FH, Sale, Hoarding, Government, New Territories, Health, Environment, Fort Street, Senior ice hockey, Cristallo, Tsing Yi, Face, Growth, Lifting, Property management

    HONG KONG, Nov 9, 2023 - (ACN Newswire) - Grand Ming Group Holdings Limited (the "Company" and together with its subsidiaries, the "Group", stock code: 1271.HK) today announces its interim results for the six months ended 30 September 2023 ("FH 2023/24").

    Key Points: 
    • HONG KONG, Nov 9, 2023 - (ACN Newswire) - Grand Ming Group Holdings Limited (the "Company" and together with its subsidiaries, the "Group", stock code: 1271.HK) today announces its interim results for the six months ended 30 September 2023 ("FH 2023/24").
    • The Group's consolidated revenue decreased by 96.1% from HK$4,920.1 million for the six months ended 30 September 2022 ("FH 2022/23") to HK$191.7 million for FH 2023/24.
    • Handover of the pre-sold units had commenced in October 2023 after the development was granted occupation permit in August 2023.
    • Mr. Chan Hung Ming, Chairman and Executive Director of Grand Ming Group Holdings concluded, "The global and Hong Kong economic situation is expected to continue to present considerable turbulence.

    IEEE EMBS Executive Committee Appoints Dr. Erika Ross Ellison as President-Elect, Along With Two New Vice Presidents

    Retrieved on: 
    Tuesday, December 19, 2023
    Technology, Medical Devices, Science, Genetics, Biotechnology, Other Manufacturing, Health, Health Technology, Engineering, Other Science, Research, Nanotechnology, Manufacturing, Software, Hardware, Data Management, Artificial Intelligence, FH, Student, Biomedical sciences, Tetraplegia, Mayo Clinic, Electrical engineering, University, Machine learning, Bachelor of Science, Signal processing, UNSW, EMBC, Speech, Doctor of Philosophy, Conference, Texas A&M University, Telstra, Clinical, Telecommunications, Biology, School, Student activities, Woman, DRS, Applied science, University of Freiburg, Molecular biology, Quality, American Speech, Neurosurgery, Growth, Aalborg University, Medical device

    Beena Ahmed and Natalie Mrachacz-Kersting were elected vice president of Conferences and vice president of Member and Student Activities, respectively.

    Key Points: 
    • Beena Ahmed and Natalie Mrachacz-Kersting were elected vice president of Conferences and vice president of Member and Student Activities, respectively.
    • “My top objective will be to establish IEEE EMBS as the largest global forum for biomedical engineers, clinicians and scientists,” said Dr. Ross Ellison.
    • She is the technical representative on the IEEE EMBS administrative committee, and served as program co-chair of EMBC 2023.
    • She is an IEEE EMBS practitioner representative, and is active on the IEEE Brain steering committee.

    Volvo has delivered its first electric trucks in Latin America

    Retrieved on: 
    Wednesday, December 20, 2023
    El Libertador, Volvo FH, SQM, FH, Volvo, Volvo Trucks, Truck, Volvo Financial Services, Automotive industry

    GOTHENBURG, Sweden, Dec. 20, 2023 /PRNewswire/ -- Volvo Trucks has delivered eight heavy electric trucks to customers in Brazil, Chile and Uruguay.

    Key Points: 
    • GOTHENBURG, Sweden, Dec. 20, 2023 /PRNewswire/ -- Volvo Trucks has delivered eight heavy electric trucks to customers in Brazil, Chile and Uruguay.
    • Volvo Trucks is continuing to enter new markets with its battery electric trucks.
    • The company has now delivered its first heavy-duty electric trucks to Latin America, with the vehicles going to customers in Brazil, Chile and Uruguay.
    • Volvo Trucks is aiming for 50% of global sales of new Volvo trucks to be electric in 2030.

    PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules

    Retrieved on: 
    Wednesday, November 15, 2023
    Capsule, Interest, Health Canada, Research, CSE, GMP, OTCQB, Entrepreneurship, MDMA, Clinical trial, NEO, Patient, FH, Batch, Monash University, MDXX, Filament, Partnership, PTSD, Pharmaceutical industry, Dietary supplement

    VANCOUVER, British Columbia, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA)(OTCQB:PMBHF), a Canadian biotechnology company dedicated to the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds, and Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7QS ) (“Filament”), a clinical-stage natural psychedelic drug development company, today announced the GMP release of a second batch of MDMA capsules encapsulated at Filament’s Metro Vancouver facility.

    Key Points: 
    • VANCOUVER, British Columbia, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA)(OTCQB:PMBHF), a Canadian biotechnology company dedicated to the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds, and Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7QS ) (“Filament”), a clinical-stage natural psychedelic drug development company, today announced the GMP release of a second batch of MDMA capsules encapsulated at Filament’s Metro Vancouver facility.
    • “With a number of regulatory changes over the past 6 months, we are pleased to have seen strong demand for our LaNeo MDMA Capsules,” said Nick Kadysh, CEO at PharmAla Biotech.
    • “With this second released batch, we’ve been incredibly proud to continue our work with the team at Filament to execute manufacture of our second batch of capsules.
    • “There is significant demand for GMP MDMA drug product and we are proud to meet that need with our industry-leading manufacturing capabilities,” said Benjamin Lightburn, CEO and Co-Founder of Filament Health.

    LIB Therapeutics Announces Appointment of Ingrid Choong, PhD as Chief Business Officer as Company Prepares BLA for Lerodalcibep

    Retrieved on: 
    Thursday, December 7, 2023
    Research, Diabetes, Clinical Trials, Cardiology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Other Science, Liberation, Doctor of Philosophy, Cardiovascular disease, Patient, FH, PCSK9, Therapy, BLA, Phase 3, CVD, Pharmaceutical industry

    LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor in development to reduce low density lipoprotein-cholesterol (LDL-C) for patients at very high and high risk of cardiovascular disease (CVD), today announced the appointment of Ingrid Choong, PhD as Chief Business Officer.

    Key Points: 
    • LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor in development to reduce low density lipoprotein-cholesterol (LDL-C) for patients at very high and high risk of cardiovascular disease (CVD), today announced the appointment of Ingrid Choong, PhD as Chief Business Officer.
    • LIB recently announced completion of LIBerate-CVD (n=922) and LIBerate-HR (n=922), the final two registration-enabling Phase 3 trials of Lerodalcibep.
    • LIB is preparing a biologics license application (BLA) for Lerodalcibep and plans for regulatory submission in 1H’24.
    • “Our mission is to make Lerodalcibep available to patients around the world as expeditiously as possible,” said David Cory, Chief Executive Officer of LIB Therapeutics.

    LIB Therapeutics Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep, a Novel Third-Generation PCSK9 Inhibitor in Development for Cardiovascular Disease

    Retrieved on: 
    Tuesday, November 14, 2023
    Science, Cardiology, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Clinical Trials, Marketing, Liberation, Cardiovascular disease, MBBS, FH, European Medicines Agency, Patient, Food, Therapy, PCSK9, CVD, Pharmaceutical industry

    LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very high and high risk of cardiovascular disease (CVD), today announced completion of LIBerate-CVD and LIBerate-HR, the final two registration-enabling Phase 3 trials for patients with CVD or at very high and high risk of CVD.

    Key Points: 
    • LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company developing Lerodalcibep, a novel, third-generation PCSK9 inhibitor for patients at very high and high risk of cardiovascular disease (CVD), today announced completion of LIBerate-CVD and LIBerate-HR, the final two registration-enabling Phase 3 trials for patients with CVD or at very high and high risk of CVD.
    • These two trials are part of the registration-enabling Phase 3 LIBerate Program which includes four key studies of 2,387 patients dosed for up to 52 weeks, with >2,200 patients continuing in an open-label extension study of 72 weeks.
    • “The global Phase 3 LIBerate program for Lerodalcibep is a large and comprehensive registration-enabling package and includes a diverse global population of patients with CVD, without CVD but at very high and high risk for CVD, and heterozygous and homozygous familial hypercholesterolemia (FH) which should support a broad label upon approval,” said David Kallend, MBBS, Chief Medical Officer of LIB Therapeutics.
    • “We look forward to working with regulators to submit a biologics license application to the Food and Drug Administration and marketing authorization application to the European Medicines Agency in 1H 2024.”